Year 2022 / Volume 114 / Number 1
Original
Low applicability of the ‘‘Six-and-twelve score” in hepatocellular carcinoma treated with Drug-Eluting Beads Transarterial Chemoembolization.

28-34

DOI: 10.17235/reed.2021.7696/2020

María Pipa-Muñiz, Andrés Castaño-García, Susana Sanmartino, Alicia Mesa, Carmen Álvarez-Navascués, María Luisa González-Diéguez, Valle Cadahía-Rodrigo, Mario Ernesto Piscoya-Díaz, Serafín Marcos Costilla-García, Manuel Rodríguez, María Varela,

Abstract
Objective: The effectiveness of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) depends on the selection of suitable patients. The ‘‘Six-and-twelve score” distinguishes three groups of ideal patients with different overall survival, based on the sum of the number and size of tumors. This may impact on clinical practice and trial design. The aim of this study was to assess the reproducibility and prognostic value of the model in western patients treated with Drug-Eluting Beads (DEB)-TACE. Methods: Observational, retrospective, unicentric study with consecutive compensated patients treated with DEB-TACE from October 2008 to October 2017. Exclusion criteria were Child-Pugh ≥ 8 and DEB-TACE used as a bridge to liver transplantation. Results: 225 HCC consecutive patients were included; BCLC-0/A n=131 (single nodules > 5, n=29) and BCLC-B n=94. The median overall survival (OS) was 27 months (95% CI 23.8-30.2). OS was different between BCLC-0/A vs BCLC-B: 30 vs 24 months (p= 0.03), Child-Pugh A5 vs A6-B7: 30 vs 27 months (p= 0.003). ‘‘Six-and-twelve score” groups discriminated OS: group 1, n=123, 32 months (95% CI 27.5-63.5), group 2, n=101, 24 months (95% CI 19.6-28.4) and group 3, n=1, 27 months (p=0.024). When comparing the three scores, the ‘‘Six-and-twelve score” showed the best discrimination power: C-index 0.603, Akaike’s information criterion (AIC) 1.642, likelihood ratio test (LRT) 16.21. Conclusion: The ‘‘Six-and-twelve score” is a prognostic tool for patients with HCC treated with DEB-TACE. However, few patients were included in the third group (score >12) and no differences were observed with BCLC, therefore its applicability is limited.  
Share Button
New comment
Comments
No comments for this article
References
1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301-14.
2. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC-B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Sem Liv Dis 2012;32(4);348-59.
3. Yamakado K, Miyayama S, Hirota S, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocelular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-5.
4. Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology 2014;87(Suppl 1):22-31.
5. Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi’s Subclassification (Kinki Criteria). Dig Dis 2015;33(6):751-8.
6. Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24(10):2565-70.
7. Pinato JD, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol 2015;13:1204-8.
8. Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 2016;36(1):100-7.
9. Cappelli A, Cucchetti A, Cabibbo G, et al. Refining prognosis after trans-arterial-chemo-embolization for hepatocellular carcinoma. Liver Int 2016;36:729-36. DOI: 10.1111/liv.13029
10. Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 2014;61(6):1287-96.
11. Sieghart W, Hucke F, Pinter M, et al. The ART of Decision Making: Retreatment With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Hepatology 2013;57(6):2261-73.
12. Adhoute X, Penaranda G, Naude S, et al. Retreatment with DEB-TACE: The ABCR SCORE, an aid to the decision-making process. J Hepatol 2015;62(4):855-62.
13. Facciorusso A, Bhoori S, Sposito C, et al. Repeated transarterial chemoembolization: An overfitting effort? J Hepatol 2015;62(6):1440-2.
14. Nam JY, Choe AR, Sinn DH, et al. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20(1):504. DOI: 10.1186/s12885-020-06975-2
15. Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol 2019;70(5):893-903.
16. Bourlière M, Pénaranda G, Adhoute X, et al. The "Six-and-twelve score" for TACE treatment: Does it really help us? J Hepatol 2019;71(5):1051-2.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
18. Pipa M, Sanmartino S, Mesa A, et al. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization. BMC Gastroenterol 2020;20(1):166. DOI: 10.1186/s12876-020-01307-x
19. Prajapati HJ, Xing M, Spivey JR, et al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads DEB-TACE chemoembolization in patients with unresectable HCC. AJR Am J Roentgenol 2014;203(6):W706-14.
20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
21. Forner A, Gilabert M, Bruix J, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014;11(9):525-35.
22. Stairmand J, Signal L, Sarfati D, et al. Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol 2015;26(7):1325-32.
23. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37(3):212-20.
24. Mancebo A, González- Diéguez ML, Cadahía V, et al. Annual Incidence of Hepatocellular Carcinoma Among Patients With Alcoholic Cirrhosis and Identification of Risk Groups. Clin Gastroenterol Hepatol 2013;11(1):95-101.
25. Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol 2019;17(11):2320-9.
26. Marot A, Henrion J, Knebel JF, et al. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS One 2017;12(10):e0186715.
27. Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70(2):284-93.
28. Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA 2018;320(8):815-24.
29. Schuckit MA. Alcohol-use disorders. Lancet 2009;373(9662):492-501. DOI: 10.1016/S0140-6736(09)60009-X
30. Cappelli A, Sangro P, Mosconi C, et al. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46(3):661-8. DOI: 10.1007/s00259-018-4152-7
Related articles

Original

Can we optimize CEA as a response marker in rectal cancer?

DOI: 10.17235/reed.2020.7321/2020

Editorial

Colorectal cancer screening and survival

DOI: 10.17235/reed.2018.5870/2018

Editorial

The right colon challenge

DOI: 10.17235/reed.2018.5544/2018

Letter to the Editor

Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity

DOI: 10.17235/reed.2017.4997/2017

Letter to the Editor

Pancreatic neuroendocrine tumors. Prognostic factors

DOI: 10.17235/reed.2017.5109/2017

Editorial

Pancreas neuroendocrine tumors - not so rare or benign

DOI: 10.17235/reed.2016.4672/2016

Original

Self-expanding metal stents in postoperative esophageal leaks

DOI: 10.17235/reed.2016.3987/2015

Citation tools
Pipa-Muñiz M, Castaño-García A, Sanmartino S, Mesa A, Álvarez-Navascués C, González-Diéguez M, et all. Low applicability of the ‘‘Six-and-twelve score” in hepatocellular carcinoma treated with Drug-Eluting Beads Transarterial Chemoembolization.. 7696/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1481 visits.
This article has been downloaded 121 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 30/11/2020

Accepted: 06/03/2021

Online First: 18/03/2021

Published: 10/01/2022

Article revision time: 94 days

Article Online First time: 108 days

Article editing time: 406 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology